Details of the Drug

General Information of Drug (ID: DMVO0UB)

Drug Name
Alfentanil
Synonyms
Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1], [2]
Therapeutic Class
Anesthetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 416.5
Topological Polar Surface Area (xlogp) 2.2
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption
The drug is only absorbed by intravenous injection or infusion [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The clearance of drug is 5 mL/min/kg [5]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 90 - 111 minutes [6]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.5882 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.086% [6]
Vd
The volume of distribution (Vd) of drug is 0.4-1 L/kg [5]
Chemical Identifiers
Formula
C21H32N6O3
IUPAC Name
N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide
Canonical SMILES
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC
InChI
InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3
InChIKey
IDBPHNDTYPBSNI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
51263
ChEBI ID
CHEBI:2569
CAS Number
71195-58-9
DrugBank ID
DB00802
TTD ID
D0G5QB
VARIDT ID
DR00617
INTEDE ID
DR0061

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Agonist [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anaesthesia
ICD Disease Classification 9A78.6
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.09E-02 -5.62E-02 -5.19E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Alfentanil
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Atracurium DM42HXN Moderate Increased risk of bradycardia by the combination of Alfentanil and Atracurium. Corneal disease [9A76-9A78] [42]
Mivacurium DM473VD Moderate Additive hypotensive effects by the combination of Alfentanil and Mivacurium. Corneal disease [9A76-9A78] [42]
Levobupivacaine DM783CH Minor Decreased metabolism of Alfentanil caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [43]
Pancuronium DMB0VY8 Moderate Additive hypotensive effects by the combination of Alfentanil and Pancuronium. Corneal disease [9A76-9A78] [42]
Propofol DMB4OLE Moderate Additive cardiorespiratory depression effects by the combination of Alfentanil and Propofol. Corneal disease [9A76-9A78] [44]
Tubocurarine DMBZIVP Moderate Increased risk of bradycardia by the combination of Alfentanil and Tubocurarine. Corneal disease [9A76-9A78] [42]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Alfentanil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Alfentanil caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [43]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Alfentanil caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [43]
Arn-509 DMT81LZ Moderate Increased metabolism of Alfentanil caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [43]
Dronedarone DMA8FS5 Major Decreased metabolism of Alfentanil caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [45]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Alfentanil and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [46]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Alfentanil and Chlormezanone. Anxiety disorder [6B00-6B0Z] [47]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Alfentanil and Oxazepam. Anxiety disorder [6B00-6B0Z] [47]
Posaconazole DMUL5EW Major Decreased metabolism of Alfentanil caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [45]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Alfentanil and Desipramine. Attention deficit hyperactivity disorder [6A05] [48]
Dalfopristin DM4LTKV Major Decreased metabolism of Alfentanil caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [42]
Troleandomycin DMUZNIG Major Decreased metabolism of Alfentanil caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Telithromycin DMZ4P3A Major Decreased metabolism of Alfentanil caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Alfentanil and Cariprazine. Bipolar disorder [6A60] [47]
Erdafitinib DMI782S Moderate Increased metabolism of Alfentanil caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [49]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Alfentanil caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Tucatinib DMBESUA Major Decreased metabolism of Alfentanil caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Palbociclib DMD7L94 Moderate Decreased metabolism of Alfentanil caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Alfentanil caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [43]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Alfentanil and Levomilnacipran. Chronic pain [MG30] [50]
Mifepristone DMGZQEF Major Decreased metabolism of Alfentanil caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [45]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Alfentanil caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [45]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Alfentanil caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [45]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Alfentanil and Ethanol. Cystitis [GC00] [51]
MK-8228 DMOB58Q Major Decreased metabolism of Alfentanil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [45]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Alfentanil and Sertraline. Depression [6A70-6A7Z] [50]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Alfentanil and Cyclobenzaprine. Depression [6A70-6A7Z] [52]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Alfentanil and Vilazodone. Depression [6A70-6A7Z] [50]
Nefazodone DM4ZS8M Major Decreased metabolism of Alfentanil caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [45]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Alfentanil and Vortioxetine. Depression [6A70-6A7Z] [50]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Alfentanil and Milnacipran. Depression [6A70-6A7Z] [50]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Alfentanil and Desvenlafaxine. Depression [6A70-6A7Z] [50]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Alfentanil and OPC-34712. Depression [6A70-6A7Z] [47]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Alfentanil and Clomipramine. Depression [6A70-6A7Z] [48]
Doxepin DMPI98T Moderate Additive serotonergic effects by the combination of Alfentanil and Doxepin. Depression [6A70-6A7Z] [48]
Maprotiline DMPWB7T Moderate Additive CNS depression effects by the combination of Alfentanil and Maprotiline. Depression [6A70-6A7Z] [48]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Alfentanil and Esketamine. Depression [6A70-6A7Z] [53]
Mepenzolate DM8YU2F Moderate Additive antimotility effects by the combination of Alfentanil and Mepenzolate. Digestive system disease [DE2Z] [54]
Oxybutynine DMJPBAX Moderate Additive antimotility effects by the combination of Alfentanil and Oxybutynine. Discovery agent [N.A.] [54]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Alfentanil and Diazepam. Epilepsy/seizure [8A61-8A6Z] [52]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Alfentanil and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [55]
Cenobamate DMGOVHA Moderate Increased metabolism of Alfentanil caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Stiripentol DMMSDOY Major Decreased metabolism of Alfentanil caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Alfentanil caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Alfentanil and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [47]
Rufinamide DMWE60C Moderate Increased metabolism of Alfentanil caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Alfentanil and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [47]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Alfentanil caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Alfentanil and Dantrolene. Fever [MG26] [47]
Tazemetostat DMWP1BH Moderate Increased metabolism of Alfentanil caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [43]
Solifenacin DMG592Q Moderate Additive antimotility effects by the combination of Alfentanil and Solifenacin. Functional bladder disorder [GC50] [54]
Tolterodine DMSHPW8 Moderate Additive antimotility effects by the combination of Alfentanil and Tolterodine. Functional bladder disorder [GC50] [54]
Itraconazole DMCR1MV Major Decreased metabolism of Alfentanil caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Ketoconazole DMPZI3Q Major Decreased metabolism of Alfentanil caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Alfentanil caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [43]
Boceprevir DMBSHMF Major Decreased metabolism of Alfentanil caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [45]
Telaprevir DMMRV29 Major Decreased metabolism of Alfentanil caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [45]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Alfentanil caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [45]
Rifampin DMA8J1G Moderate Increased metabolism of Alfentanil caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [43]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Alfentanil caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Cobicistat DM6L4H2 Major Decreased metabolism of Alfentanil caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Saquinavir DMG814N Major Decreased metabolism of Alfentanil caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Etravirine DMGV8QU Moderate Increased metabolism of Alfentanil caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Darunavir DMN3GCH Major Decreased metabolism of Alfentanil caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Atazanavir DMSYRBX Major Decreased metabolism of Alfentanil caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Alfentanil caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [45]
Conivaptan DM1V329 Major Decreased metabolism of Alfentanil caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [45]
Lesinurad DMUR64T Moderate Increased metabolism of Alfentanil caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [56]
Belladonna DM2RBWK Moderate Additive CNS depression effects by the combination of Alfentanil and Belladonna. Infectious gastroenteritis/colitis [1A40] [54]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Alfentanil and Suvorexant. Insomnia [7A00-7A0Z] [47]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Alfentanil and Amobarbital. Insomnia [7A00-7A0Z] [47]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Alfentanil and Zaleplon. Insomnia [7A00-7A0Z] [47]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Alfentanil and Tasimelteon. Insomnia [7A00-7A0Z] [47]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Alfentanil and Paraldehyde. Insomnia [7A00-7A0Z] [47]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Alfentanil and ITI-007. Insomnia [7A00-7A0Z] [47]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Alfentanil and Quazepam. Insomnia [7A00-7A0Z] [47]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Alfentanil and Estazolam. Insomnia [7A00-7A0Z] [47]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Alfentanil and Polyethylene glycol. Irritable bowel syndrome [DD91] [57]
Dicyclomine DMZSDGX Moderate Additive CNS depression effects by the combination of Alfentanil and Dicyclomine. Irritable bowel syndrome [DD91] [54]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Alfentanil and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [47]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Alfentanil caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [58]
Crizotinib DM4F29C Major Decreased metabolism of Alfentanil caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [45]
Brigatinib DM7W94S Moderate Increased metabolism of Alfentanil caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [43]
Ceritinib DMB920Z Major Decreased metabolism of Alfentanil caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [45]
PF-06463922 DMKM7EW Moderate Increased metabolism of Alfentanil caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [59]
Osimertinib DMRJLAT Moderate Decreased metabolism of Alfentanil caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [58]
Selpercatinib DMZR15V Moderate Decreased metabolism of Alfentanil caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [45]
Idelalisib DM602WT Major Decreased metabolism of Alfentanil caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [45]
IPI-145 DMWA24P Major Decreased metabolism of Alfentanil caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [45]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Alfentanil caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [60]
Vemurafenib DM62UG5 Moderate Increased metabolism of Alfentanil caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [43]
LGX818 DMNQXV8 Moderate Increased metabolism of Alfentanil caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [61]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Alfentanil caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [58]
Danazol DML8KTN Moderate Decreased metabolism of Alfentanil caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [45]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Alfentanil and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [62]
Exjade DMHPRWG Moderate Increased metabolism of Alfentanil caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [43]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Alfentanil and Flibanserin. Mood disorder [6A60-6E23] [63]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Alfentanil and Thalidomide. Multiple myeloma [2A83] [64]
Fedratinib DM4ZBK6 Major Decreased metabolism of Alfentanil caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [45]
Nilotinib DM7HXWT Moderate Decreased metabolism of Alfentanil caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [45]
Dasatinib DMJV2EK Moderate Decreased metabolism of Alfentanil caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [45]
Prasugrel DM7MT6E Moderate Altered absorption of Alfentanil due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [65]
Metoclopramide DMFA5MY Moderate Additive antimotility effects by the combination of Alfentanil and Metoclopramide. Nausea/vomiting [MD90] [66]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Alfentanil and Ondansetron. Nausea/vomiting [MD90] [67]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Alfentanil and Bupropion. Nicotine use disorder [6C4A] [68]
Entrectinib DMMPTLH Moderate Decreased metabolism of Alfentanil caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [45]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Alfentanil and Sibutramine. Obesity [5B80-5B81] [69]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Alfentanil and Lorcaserin. Obesity [5B80-5B81] [70]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Alfentanil and Dexfenfluramine. Obesity [5B80-5B81] [50]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Alfentanil and Apraclonidine. Optic nerve disorder [9C40] [71]
Olaparib DM8QB1D Moderate Decreased metabolism of Alfentanil caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [53]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Alfentanil caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [45]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Alfentanil and Flavoxate. Pain [MG30-MG3Z] [54]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Alfentanil and Biperiden. Parkinsonism [8A00] [72]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Alfentanil and Pimavanserin. Parkinsonism [8A00] [47]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Alfentanil and Orphenadrine. Parkinsonism [8A00] [47]
Abametapir DM2RX0I Moderate Decreased metabolism of Alfentanil caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [73]
Methylscopolamine DM5VWOB Moderate Additive antimotility effects by the combination of Alfentanil and Methylscopolamine. Peptic ulcer [DA61] [54]
Lefamulin DME6G97 Moderate Decreased metabolism of Alfentanil caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [74]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Alfentanil caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [45]
Enzalutamide DMGL19D Moderate Increased metabolism of Alfentanil caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [43]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Alfentanil caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [45]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Alfentanil and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [75]
Dexamethasone DMMWZET Moderate Increased metabolism of Alfentanil caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [43]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Alfentanil and Quetiapine. Schizophrenia [6A20] [76]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Alfentanil and Mesoridazine. Schizophrenia [6A20] [76]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Alfentanil and Aripiprazole. Schizophrenia [6A20] [47]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Alfentanil and Iloperidone. Schizophrenia [6A20] [47]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Alfentanil and Paliperidone. Schizophrenia [6A20] [47]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Alfentanil and Perphenazine. Schizophrenia [6A20] [47]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Alfentanil and Molindone. Schizophrenia [6A20] [47]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Alfentanil and Thiothixene. Schizophrenia [6A20] [76]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Alfentanil and Trifluoperazine. Schizophrenia [6A20] [47]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Alfentanil and Pimozide. Schizophrenia [6A20] [47]
Mepivacaine DMH2NMY Minor Decreased metabolism of Alfentanil caused by Mepivacaine mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [43]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Alfentanil caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [45]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Alfentanil caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [58]
Larotrectinib DM26CQR Moderate Decreased metabolism of Alfentanil caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [45]
Armodafinil DMGB035 Minor Increased metabolism of Alfentanil caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [77]
LEE011 DMMX75K Moderate Decreased metabolism of Alfentanil caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [45]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Alfentanil caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [78]
Brilinta DMBR01X Moderate Decreased metabolism of Alfentanil caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [58]
Pipecuronium DM5F84A Moderate Additive hypotensive effects by the combination of Alfentanil and Pipecuronium. Tonus and reflex abnormality [MB47] [42]
Vecuronium DMP0UK2 Moderate Increased risk of bradycardia by the combination of Alfentanil and Vecuronium. Tonus and reflex abnormality [MB47] [42]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Alfentanil and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [75]
Elagolix DMB2C0E Moderate Increased metabolism of Alfentanil caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [43]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Alfentanil caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [45]
⏷ Show the Full List of 146 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7108).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075221.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
9 Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005 Mar;102(3):550-6.
10 Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 Oct;82(4):410-26.
11 Drug Interactions Flockhart Table
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
22 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
23 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
24 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
25 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
26 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
28 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
29 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
30 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
31 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
32 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
33 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
34 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
35 Clinical pipeline report, company report or official report of signaturerx.
36 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
37 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
38 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
39 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
40 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
41 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
42 Product Information. Alfenta (alfentanil). Janssen Pharmaceutica, Titusville, NJ.
43 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
44 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
45 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
46 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
47 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
48 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
49 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
50 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
51 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
52 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
53 Cerner Multum, Inc. "Australian Product Information.".
54 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
55 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
56 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
58 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
59 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
61 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
62 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
63 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
64 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
65 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
66 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
67 Canadian Pharmacists Association.
68 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
69 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
70 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
71 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
72 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
73 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
74 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
75 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
76 Cerner Multum, Inc. "Canadian Product Information.".
77 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
78 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.